Sources | Names Used |
---|---|
CTRPv2 | doxorubicin:navitoclax (2:1 mol/mol) |
PharmacoGx | doxorubicin:navitoclax (2:1 mol/mol) |
Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | SBDS | CTRPv2 | pan-cancer | AAC | -0.2 | 2e-08 |
mRNA | FHL2 | CTRPv2 | pan-cancer | AAC | -0.19 | 4e-08 |
mRNA | UBTD1 | CTRPv2 | pan-cancer | AAC | -0.19 | 8e-07 |
mRNA | CTSA | CTRPv2 | pan-cancer | AAC | -0.18 | 3e-07 |
mRNA | REXO2 | CTRPv2 | pan-cancer | AAC | -0.18 | 2e-08 |
mRNA | AHNAK | CTRPv2 | pan-cancer | AAC | -0.18 | 3e-07 |
mRNA | SERINC3 | CTRPv2 | pan-cancer | AAC | -0.18 | 2e-07 |
mRNA | HTATIP2 | CTRPv2 | pan-cancer | AAC | -0.18 | 3e-06 |
mRNA | RP11-212D19.4 | CTRPv2 | pan-cancer | AAC | -0.18 | 8e-08 |
mRNA | ATP6V0E1 | CTRPv2 | pan-cancer | AAC | -0.18 | 1e-06 |